Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug‐Eluting Stent Implantation
Journal of the American Heart Association · 05.05.2026 · 15 (9)
DOI: 10.1161/jaha.125.045981 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 05.05.2026. Verfasst von Soo-Jin Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine Kosin University College of Medicine Busan Korea. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Drug-Eluting Stents, Percutaneous Coronary Intervention, Acute Coronary Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Dual‐antiplatelet therapy is standard after percutaneous coronary intervention, but clopidogrel responsiveness varies with CYP2C19 loss‐of‐function alleles. Whether the genotype conveys different prognostic significance between sexes is uncertain.
Methods
We analyzed 4630 East‐Asian patients with acute coronary syndrome in the PTRG‐DES (Platelet Function– and Genotype‐Related Long‐Term Prognosis in Drug‐Eluting Stent–Treated Patients With Coronary Artery Disease) consortium with available CYP2C19 genotyping. Patients were classified as rapid/normal metabolizers versus intermediate/poor metabolizers. The primary end point was cardiac death, myocardial infarction, or definite stent thrombosis within 5 years.
Results
Among 4630 patients with acute coronary syndrome, 1708 (36.9%) were women. The prevalence of intermediate/poor metabolizer phenotypes was similar in women (61.8%) and men (62.5%). After multivariable adjustment for clinical, laboratory, and procedural confounders, intermediate/poor metabolizer carriers had a significantly higher risk of the 5‐year primary outcome in men compared with rapid/normal metabolizer carriers (adjusted hazard ratio [HR], 3.27 [95% CI, 1.58–6.74]; P =0.001). In contrast, no significant association was observed in women (adjusted HR, 1.21 [95% CI, 0.58–2.52]; P = 0.615). Intermediate/poor metabolizer status was also associated with a higher risk of 5‐year cardiac death in men only (adjusted HR, 7.01 [95% CI, 2.01–24.48]; P =0.002). Significant interactions between sex and CYP2C19 metabolizer status were observed for both the primary outcome ( P for interaction=0.034) and cardiac death ( P for interaction=0.049).
Conclusions
CYP2C19 loss‐of‐function allele status was a significant predictor of long‐term adverse cardiovascular outcomes in men but not in women, suggesting a sex‐specific prognostic difference in patients with acute coronary syndrome undergoing percutaneous coronary intervention. REGISTRATION URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04734028.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine Kosin University College of Medicine Busan Korea.
- Division of Cardiology, Department of Internal Medicine Kangwon National University School of Medicine Chuncheon Korea.
- Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital Korea University College of Medicine Seoul Korea.
- Division of Cardiology, Department of Internal Medicine, College of Medicine Catholic University of Korea Seoul Korea.
- Severance Cardiovascular Hospital Yonsei University College of Medicine Seoul Korea.
- Division of Cardiology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea.
ORCID-Profile: Soo-Jin Kim, Ae-Young Her, Hyung Joon Joo, Kiyuk Chang, Byeong-Keuk Kim, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Sang Yeup Lee, Jung Rae Cho, Hyo-Soo Kim, Young-Hoon Jeong, Moo Hyun Kim, Do-Sun Lim, Eun-Seok Shin
Zitieren
APA
Kim, S. J., Her, A. Y., Joo, H. J., Chang, K., Kim, B. K., Song, Y. B., Ahn, S. G., Suh, J. W., Lee, S. Y., Cho, J. R., Kim, H. S., Jeong, Y. H., Kim, M. H., Lim, D. S., & Shin, E. S. (2026). Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug‐Eluting Stent Implantation. Journal of the American Heart Association, 15(9). https://doi.org/10.1161/jaha.125.045981
Vancouver
Kim SJ, Her AY, Joo HJ, Chang K, Kim BK, Song YB, et al. Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug‐Eluting Stent Implantation. Journal of the American Heart Association. 2026;15(9). doi:10.1161/jaha.125.045981
BibTeX
@article{Kim2026,
author = {Kim, Soo-Jin and Her, Ae-Young and Joo, Hyung Joon and Chang, Kiyuk and Kim, Byeong-Keuk and Song, Young Bin and Ahn, Sung Gyun and Suh, Jung-Won and Lee, Sang Yeup and Cho, Jung Rae and Kim, Hyo-Soo and Jeong, Young-Hoon and Kim, Moo Hyun and Lim, Do-Sun and Shin, Eun-Seok},
title = {Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug‐Eluting Stent Implantation},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {9},
doi = {10.1161/jaha.125.045981}
}
EUVIMED